7871.Two
The company operates in the healthcare diagnostics segment, providing products and services related to medical testing and diagnostic solutions.
Business. The company operates in the healthcare diagnostics segment, providing products and services related to medical testing and diagnostic solutions.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the healthcare diagnostics segment, providing products and services related to medical testing and diagnostic solutions.
The company's capital structure is highly leveraged, with total liabilities of TWD 141.65 billion and total equity of TWD -126.79 billion, resulting in a negative debt-to-equity ratio of -0.03. Liquidity is constrained, as evidenced by a current ratio of 0.07, indicating the company has insufficient current assets to cover its current liabilities. The valuation snapshot reveals a negative return on assets of -2.96%, suggesting the company is not effectively utilizing its assets to generate profit.
Profitability is severely challenged, with a net loss of TWD 440.32 billion and an operating loss of TWD 217.19 billion, indicating the company is not generating positive operating income. The return on equity of 0.3473 is also weak, reflecting poor performance in generating returns for shareholders. These metrics fall significantly below the industry norms for a biotechnology and medical research firm, highlighting the company's financial distress.
The company's revenue concentration is not disclosed in the available data, but the negative net income and operating cash flow suggest a lack of stable revenue streams. There is no information on geographic exposure or segment performance, which limits the ability to assess diversification and risk.
The company's growth trajectory is negative, with a net loss and declining cash flows. The operating cash flow of TWD -239.70 billion and free cash flow of TWD -442.93 billion indicate the company is not generating sufficient cash to sustain operations or fund growth. The capital expenditure of TWD -9.97 billion suggests the company is not investing in long-term growth.
The risk assessment highlights significant liquidity risk, with a current ratio of 0.07 and negative net cash after subtracting total debt. The dilution risk is low, but the company's negative equity and high liabilities increase the potential for future dilution if the company requires additional capital. The valuation adjustments applied in the custom valuations reflect the company's poor financial performance and high risk profile.
Recent events, such as the company's financial performance and cash flow issues, are reflected in the latest financial statements. There is no indication of significant recent filings or transcripts that would suggest a change in the company's financial strategy or outlook.
- The company is experiencing significant financial distress, with a net loss and negative operating and free cash flows.
- The capital structure is highly leveraged, with total liabilities far exceeding total equity.
- The company's liquidity is constrained, as indicated by a very low current ratio.
- The return on equity and return on assets are weak, reflecting poor performance in generating returns for shareholders.
- The company is not investing in long-term growth, as evidenced by the negative capital expenditure.
- "margin_outlook_rationale": "The company's margin outlook is negative due to the significant net loss and operating loss, indicating poor cost control and pricing power.",
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- 7871.TWO Market data — financials · 2026-05-27